A prospective study of peri-transplant sorafenib for FLT3-ITD AML patients undergoing allogeneic transplantation.

Keith W Pratz,Michelle A Rudek,B Douglas Smith,Judith Karp,Ivana Gojo,Amy Dezern,Richard J Jones,Jackie Greer,Christopher Gocke,Maria R Baer,Vu H Duong,Gary Rosner,Marianna Zahurak,John J Wright,Ashkan Emadi,Mark Levis

Biology of Blood and Marrow Transplantation（2020）

引用 31|浏览67

暂无评分

摘要

•Sorafenib is safe and well tolerated before and after transplant if dosed according to patient adverse effects.•Sorafenib use after transplant is associated with encouraging post-transplant survival in patients with FLT3-ITD acute myeloid leukemia undergoing hematopoietic stem cell transplant.•Sorafenib dosing according to patient tolerance achieves target suppression of FLT3-ITD.

查看译文

关键词

Post-transplant,Maintenance,FLT3

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要